Phaseline

Companies › Context Therapeutics

Context Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CTIM-76
CLDN6-directed T cell-engaging bispecific antibody
CLDN6Phase 1Platinum-resistant Ovarian CancerMay 2028
CT-202
Nectin-4 directed bispecific antibody engaging T cells
NECTIN4Phase 1Triple Negative Breast Cancer (TNBC)Jan 2030
CT-95
MSLN bispecific antibody
MSLNPhase 1Mesothelin-Expressing Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06756035CT-95Phase 1Mesothelin-Expressing TumorsOncologyOct 2026
NCT06515613CTIM-76Phase 1Platinum-resistant Ovarian CancerOncologyMay 2028
NCT07545122CT-202Phase 1Triple Negative Breast Cancer (TNBC)OncologyJan 2030

From the company's SEC filings

Cash of $43m on 2026-06-30; operating cash outflow about $37m a year; runway about 14 months at that burn, to Aug 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CLDN6 (1) NECTIN4 (1) MSLN (1)

Companies with the same targets

Beijing Biotech BicycleTx BioNTech Cell & Gene Therapies A2 Biotherapeutics BeOne Medicines NovaRock Biotherapeutics Mabwell (Shanghai) Bioscience Aktis Oncology Tianjin ConjuStar Biologics Regeneron Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.